Navigation Links
Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
Date:10/21/2013

CHICAGO, Oct. 21, 2013 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting to be held October 25 – 30, in San Diego, CA at the San Diego Convention Center.

"We're encouraged by the data each of these studies have generated as it provides additional validation for our unique approach to delivering a broad dosing range of methotrexate to patients with rheumatoid arthritis," remarked Terri Shoemaker, President and CEO of Medac Pharma, Inc.  "Our primary goal is to provide this extremely underserved patient population with a more personalized delivery technique to managing their disease, and we believe we're on track for accomplishing that through our unique approach."

The posters will highlight Medac Pharma Inc.'s rationale for the development of its lead product by presenting data on relative bioavailability and ease of self-administration.

Monday, October 28, 2013:Title:Successful Self-Administration of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector PenTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract #1354Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)Title:Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of MethotrexateTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract # 1355Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)About Medac Pharma, Inc.Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.

Medac Pharma Inc. is focused on developing therapies with the potential to make meaningful differences in patients' lives.  The company's approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.

For more information, please visit www.medacpharma.com.

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Medac Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
2. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
3. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
4. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
5. NovoBioPharma, Partnership of Top Life Science Experts, Launches
6. Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
7. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
8. Zosano Pharma, Inc. Announces Key Strategic Hire
9. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
10. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
11. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
(Date:12/8/2016)... 2016 KEY FINDINGS ... Patient warming and cooling ... during surgeries, lowering the risks of neurological disorders post cardiac ... The patient warming systems can be segmented into convective warming ... turn reduce the stay at hospitals thus, lowering the healthcare ...
(Date:12/8/2016)... Inc. (NYSE: DPLO) has been recognized by the Detroit Free ... To learn more about Diplomat,s career opportunities, visit ... ... ... a research firm specializing in organizational health and workplace improvement. The ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... An inventor from Cana, Va., wanted to fulfill the need ... park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. ... set up in a matter of minutes, or even seconds. The SAFETY STRAP FOR ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... will become Quality Insights beginning January 1, 2017. The name change aligns ... commitment to measuring and improving health care quality. , “We are very proud ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
Breaking Medicine News(10 mins):